Bristol Myers Squibb stock holds firm after a Q2 beat
Published on 08/23/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb (US0897961004) stock is backed by a July 30, 2026 quarter that brought $2.04 in adjusted EPS on $12.97 billion in revenue, while the stock opened at $67.06 and the company carried a market cap of $136.98 billion on August 23, 2026.
The quarter was a clear comparison with the same period a year earlier, when EPS was $1.46, and revenue also topped the consensus view of $11.74 billion by a wide margin. The latest guidance points to $6.75 to $7.00 in full-year EPS for fiscal 2026, while analysts were centered at $6.95.
July 30 still matters
The most recent reported quarter remains the core driver for Bristol Myers Squibb shares because the earnings gap was not small: EPS beat by $0.44, or 27.5 percent, versus the $1.60 consensus estimate. Revenue also exceeded expectations by $1.23 billion, a 10.5 percent beat against the $11.74 billion estimate.
That combination leaves the current narrative tied to execution rather than speculation. A market cap above $136 billion and a forward EPS guide that brackets the analyst view give the stock a valuation and earnings frame that investors can compare directly with peers.
What the numbers imply
The revenue line also showed 5.7 percent year-over-year growth, which matters because Bristol Myers Squibb is still being judged on whether its portfolio can keep offsetting patent pressure elsewhere in large-cap pharma. The net margin of 18.87 percent and return on equity of 66.90 percent add another layer to that debate.
The stock's opening level of $67.06 on August 23, 2026 sits alongside a reported market cap of $136.98 billion, which gives investors a simple reference point for how the market is pricing the latest quarter. With guidance at $6.75 to $7.00 EPS for fiscal 2026, the next swing factor is whether execution keeps the company inside that range.
Opdivo stays central
Opdivo remains one of Bristol Myers Squibb's most visible products and a key contributor to the company's oncology footprint. That product mix still matters because the latest quarter and the full-year guide both depend on durable demand across the core portfolio.
Stock level
Bristol Myers Squibb stock traded at $67.06 on August 23, 2026, while the reported market cap stood at $136.98 billion. The same-day picture is defined less by a fresh headline than by the July 30 earnings beat and the full-year EPS guide.
Fact box
Company: Bristol Myers Squibb Company
ISIN: US0897961004
Ticker: BMY
Exchange: NYSE
Price (as of August 23, 2026): $67.06 USD
Market cap: $136.98 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
